Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Stiffness | 9 | 2023 | 72 | 4.360 |
Why?
|
| Hypertension | 17 | 2024 | 1329 | 4.280 |
Why?
|
| Blood Pressure | 19 | 2024 | 1369 | 3.880 |
Why?
|
| Dyslipidemias | 12 | 2023 | 235 | 2.830 |
Why?
|
| Cardiovascular Diseases | 13 | 2024 | 1958 | 1.900 |
Why?
|
| Adipokines | 3 | 2017 | 60 | 1.570 |
Why?
|
| Obesity | 9 | 2023 | 2248 | 1.450 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 5 | 2022 | 54 | 1.420 |
Why?
|
| Pulse Wave Analysis | 7 | 2023 | 46 | 1.370 |
Why?
|
| Aortic Coarctation | 2 | 2023 | 110 | 1.340 |
Why?
|
| Hypolipidemic Agents | 3 | 2016 | 181 | 1.310 |
Why?
|
| American Heart Association | 9 | 2024 | 322 | 1.290 |
Why?
|
| Hypertrophy, Left Ventricular | 5 | 2025 | 109 | 1.280 |
Why?
|
| Echocardiography | 5 | 2025 | 1053 | 1.240 |
Why?
|
| Lipids | 4 | 2020 | 521 | 1.170 |
Why?
|
| Mass Screening | 4 | 2021 | 772 | 1.160 |
Why?
|
| Adolescent | 39 | 2025 | 19221 | 1.120 |
Why?
|
| Rheumatic Heart Disease | 2 | 2018 | 38 | 1.050 |
Why?
|
| Atherosclerosis | 3 | 2023 | 920 | 0.990 |
Why?
|
| Insulin Resistance | 4 | 2025 | 640 | 0.960 |
Why?
|
| Hyperglycemia | 2 | 2025 | 225 | 0.920 |
Why?
|
| Pediatric Obesity | 3 | 2020 | 383 | 0.910 |
Why?
|
| Environmental Exposure | 2 | 2024 | 219 | 0.890 |
Why?
|
| Risk Factors | 22 | 2024 | 10249 | 0.880 |
Why?
|
| Body Mass Index | 7 | 2021 | 1562 | 0.860 |
Why?
|
| Child | 34 | 2024 | 24173 | 0.840 |
Why?
|
| Pediatrics | 5 | 2021 | 1144 | 0.830 |
Why?
|
| Ductus Arteriosus | 1 | 2023 | 62 | 0.810 |
Why?
|
| Hyperinsulinism | 1 | 2023 | 67 | 0.810 |
Why?
|
| Life Style | 3 | 2021 | 414 | 0.800 |
Why?
|
| Hemodynamics | 4 | 2017 | 852 | 0.780 |
Why?
|
| Aorta | 3 | 2023 | 547 | 0.760 |
Why?
|
| Blood Pressure Determination | 2 | 2024 | 110 | 0.750 |
Why?
|
| Referral and Consultation | 2 | 2016 | 538 | 0.740 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2021 | 4 | 0.730 |
Why?
|
| Male | 46 | 2025 | 61317 | 0.720 |
Why?
|
| Metabolic Syndrome | 4 | 2021 | 341 | 0.700 |
Why?
|
| Humans | 63 | 2025 | 124705 | 0.690 |
Why?
|
| Young Adult | 14 | 2025 | 9023 | 0.660 |
Why?
|
| Female | 44 | 2025 | 66577 | 0.650 |
Why?
|
| Nutrition Surveys | 2 | 2018 | 293 | 0.640 |
Why?
|
| Lead | 1 | 2018 | 23 | 0.610 |
Why?
|
| Cross-Sectional Studies | 9 | 2019 | 3415 | 0.580 |
Why?
|
| Manometry | 1 | 2017 | 48 | 0.580 |
Why?
|
| Longitudinal Studies | 7 | 2025 | 1326 | 0.580 |
Why?
|
| Child of Impaired Parents | 1 | 2017 | 15 | 0.560 |
Why?
|
| Healthy Lifestyle | 1 | 2016 | 31 | 0.530 |
Why?
|
| Biomarkers | 10 | 2019 | 3083 | 0.520 |
Why?
|
| Body Weight | 1 | 2020 | 990 | 0.520 |
Why?
|
| Aorta, Thoracic | 1 | 2021 | 531 | 0.510 |
Why?
|
| Heart Defects, Congenital | 2 | 2023 | 1816 | 0.510 |
Why?
|
| Population Surveillance | 1 | 2018 | 386 | 0.510 |
Why?
|
| Office Visits | 1 | 2016 | 77 | 0.500 |
Why?
|
| Models, Econometric | 1 | 2015 | 9 | 0.480 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2014 | 12 | 0.470 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2016 | 156 | 0.460 |
Why?
|
| Markov Chains | 1 | 2015 | 83 | 0.460 |
Why?
|
| Heart Rate | 1 | 2017 | 589 | 0.460 |
Why?
|
| Incidence | 7 | 2021 | 3115 | 0.450 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2011 | 38 | 0.450 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 218 | 0.420 |
Why?
|
| Primary Prevention | 1 | 2014 | 171 | 0.420 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 732 | 0.420 |
Why?
|
| Accessory Atrioventricular Bundle | 1 | 2012 | 8 | 0.410 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2013 | 42 | 0.410 |
Why?
|
| Electronic Health Records | 2 | 2017 | 722 | 0.410 |
Why?
|
| United States | 14 | 2024 | 10866 | 0.400 |
Why?
|
| Practice Guidelines as Topic | 4 | 2021 | 1260 | 0.400 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2012 | 16 | 0.400 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2012 | 50 | 0.390 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 1437 | 0.390 |
Why?
|
| Ventricular Fibrillation | 1 | 2012 | 51 | 0.380 |
Why?
|
| Carotid Artery Diseases | 1 | 2013 | 148 | 0.380 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 872 | 0.380 |
Why?
|
| Medication Adherence | 1 | 2016 | 393 | 0.370 |
Why?
|
| Adult | 17 | 2023 | 29554 | 0.370 |
Why?
|
| Prevalence | 7 | 2018 | 2446 | 0.360 |
Why?
|
| Antihypertensive Agents | 3 | 2024 | 412 | 0.350 |
Why?
|
| Triglycerides | 3 | 2020 | 577 | 0.350 |
Why?
|
| Health Policy | 1 | 2013 | 212 | 0.350 |
Why?
|
| Sex Factors | 4 | 2020 | 1287 | 0.340 |
Why?
|
| Catheter Ablation | 1 | 2012 | 233 | 0.340 |
Why?
|
| Tachycardia, Ventricular | 1 | 2012 | 192 | 0.330 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2009 | 86 | 0.310 |
Why?
|
| Cardiology | 2 | 2024 | 504 | 0.300 |
Why?
|
| Heart Diseases | 1 | 2012 | 492 | 0.290 |
Why?
|
| Arterial Pressure | 2 | 2019 | 112 | 0.290 |
Why?
|
| Retinol-Binding Proteins, Plasma | 2 | 2017 | 15 | 0.290 |
Why?
|
| alpha-2-HS-Glycoprotein | 2 | 2017 | 7 | 0.290 |
Why?
|
| Receptors, Leptin | 2 | 2017 | 41 | 0.280 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2017 | 31 | 0.280 |
Why?
|
| Myocardium | 2 | 2012 | 1020 | 0.280 |
Why?
|
| Prospective Studies | 8 | 2019 | 6132 | 0.270 |
Why?
|
| Cohort Studies | 6 | 2024 | 4799 | 0.270 |
Why?
|
| Adiponectin | 2 | 2017 | 114 | 0.270 |
Why?
|
| Cholesterol, HDL | 3 | 2020 | 359 | 0.270 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 588 | 0.260 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2023 | 74 | 0.250 |
Why?
|
| Leptin | 2 | 2017 | 214 | 0.250 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 442 | 0.250 |
Why?
|
| Diet | 2 | 2023 | 1141 | 0.240 |
Why?
|
| Retrospective Studies | 7 | 2018 | 16263 | 0.240 |
Why?
|
| Heart Ventricles | 2 | 2009 | 769 | 0.240 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 5154 | 0.230 |
Why?
|
| Child, Preschool | 7 | 2024 | 13882 | 0.230 |
Why?
|
| Middle Aged | 11 | 2017 | 26884 | 0.220 |
Why?
|
| Environmental Pollutants | 1 | 2024 | 68 | 0.210 |
Why?
|
| Facial Pain | 1 | 2003 | 7 | 0.210 |
Why?
|
| Odds Ratio | 2 | 2017 | 1253 | 0.210 |
Why?
|
| Facial Paralysis | 1 | 2003 | 35 | 0.210 |
Why?
|
| Risk Assessment | 5 | 2023 | 3444 | 0.210 |
Why?
|
| Insulin | 2 | 2023 | 1204 | 0.210 |
Why?
|
| Age Factors | 6 | 2019 | 2807 | 0.210 |
Why?
|
| Massachusetts | 3 | 2019 | 126 | 0.200 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2024 | 171 | 0.200 |
Why?
|
| Migraine Disorders | 1 | 2003 | 63 | 0.200 |
Why?
|
| Amlodipine | 1 | 2021 | 23 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 505 | 0.190 |
Why?
|
| Boston | 4 | 2017 | 109 | 0.190 |
Why?
|
| Masked Hypertension | 1 | 2021 | 1 | 0.190 |
Why?
|
| Longevity | 1 | 2023 | 138 | 0.190 |
Why?
|
| Logistic Models | 2 | 2017 | 1807 | 0.190 |
Why?
|
| Regression Analysis | 2 | 2020 | 778 | 0.190 |
Why?
|
| White Coat Hypertension | 1 | 2021 | 10 | 0.190 |
Why?
|
| Receptor, TIE-2 | 2 | 2012 | 12 | 0.180 |
Why?
|
| Angiopoietin-2 | 2 | 2012 | 13 | 0.180 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2009 | 805 | 0.180 |
Why?
|
| Databases, Factual | 2 | 2016 | 1176 | 0.170 |
Why?
|
| Prognosis | 3 | 2019 | 4620 | 0.170 |
Why?
|
| Blood Glucose | 3 | 2025 | 1136 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 2161 | 0.160 |
Why?
|
| Cardiovascular System | 1 | 2020 | 106 | 0.160 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2019 | 33 | 0.160 |
Why?
|
| Reference Values | 1 | 2020 | 715 | 0.160 |
Why?
|
| Alanine Transaminase | 1 | 2019 | 157 | 0.150 |
Why?
|
| Brazil | 1 | 2018 | 121 | 0.150 |
Why?
|
| Glucose | 1 | 2023 | 879 | 0.150 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2021 | 205 | 0.140 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 134 | 0.140 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 106 | 0.140 |
Why?
|
| Electric Impedance | 1 | 2017 | 59 | 0.140 |
Why?
|
| Heredity | 1 | 2017 | 15 | 0.140 |
Why?
|
| Health Behavior | 2 | 2020 | 385 | 0.140 |
Why?
|
| Pulse | 1 | 2017 | 29 | 0.140 |
Why?
|
| Coronary Disease | 3 | 2011 | 676 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2017 | 1270 | 0.140 |
Why?
|
| Creatine Kinase | 1 | 2017 | 58 | 0.140 |
Why?
|
| Cholesterol, LDL | 2 | 2019 | 570 | 0.130 |
Why?
|
| Recurrence | 2 | 2015 | 1415 | 0.130 |
Why?
|
| Muscular Diseases | 1 | 2017 | 104 | 0.130 |
Why?
|
| Endothelium, Vascular | 1 | 2019 | 529 | 0.130 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2016 | 76 | 0.120 |
Why?
|
| Benchmarking | 1 | 2016 | 134 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2016 | 314 | 0.120 |
Why?
|
| Insurance Claim Review | 1 | 2015 | 27 | 0.120 |
Why?
|
| Northern Territory | 1 | 2015 | 1 | 0.120 |
Why?
|
| Penicillin G Benzathine | 1 | 2015 | 18 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2016 | 138 | 0.120 |
Why?
|
| Rheumatic Fever | 1 | 2015 | 18 | 0.120 |
Why?
|
| Exercise | 1 | 2021 | 817 | 0.120 |
Why?
|
| Disease Progression | 1 | 2021 | 2057 | 0.120 |
Why?
|
| Demography | 1 | 2015 | 239 | 0.110 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 110 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 343 | 0.110 |
Why?
|
| ROC Curve | 1 | 2016 | 568 | 0.110 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2015 | 84 | 0.110 |
Why?
|
| Patient Identification Systems | 1 | 2013 | 3 | 0.110 |
Why?
|
| Drug Recalls | 1 | 2013 | 4 | 0.110 |
Why?
|
| Vascular Remodeling | 1 | 2014 | 41 | 0.110 |
Why?
|
| Drug Contamination | 1 | 2013 | 37 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 119 | 0.110 |
Why?
|
| Pedigree | 1 | 2017 | 1604 | 0.110 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 79 | 0.110 |
Why?
|
| Health Promotion | 1 | 2016 | 388 | 0.100 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 25 | 0.100 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2012 | 22 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 800 | 0.100 |
Why?
|
| Pyrroles | 1 | 2013 | 182 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2021 | 12364 | 0.100 |
Why?
|
| Electrophysiology | 1 | 2012 | 270 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2012 | 54 | 0.100 |
Why?
|
| Blood Flow Velocity | 2 | 2012 | 457 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2015 | 384 | 0.100 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 97 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 143 | 0.090 |
Why?
|
| Ventricular Remodeling | 2 | 2025 | 184 | 0.090 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 139 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2013 | 237 | 0.090 |
Why?
|
| Heart Valve Prosthesis | 1 | 2015 | 301 | 0.090 |
Why?
|
| Aged | 4 | 2017 | 19830 | 0.090 |
Why?
|
| Inflammation | 1 | 2018 | 1440 | 0.090 |
Why?
|
| Fibrosis | 1 | 2012 | 435 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 822 | 0.090 |
Why?
|
| Linear Models | 1 | 2012 | 682 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 341 | 0.080 |
Why?
|
| Genotype | 1 | 2016 | 2558 | 0.080 |
Why?
|
| Truncus Arteriosus | 1 | 2009 | 13 | 0.080 |
Why?
|
| Phenotype | 1 | 2019 | 4258 | 0.080 |
Why?
|
| Aging | 2 | 2010 | 1183 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2013 | 938 | 0.080 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2009 | 133 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3293 | 0.070 |
Why?
|
| Tetralogy of Fallot | 1 | 2009 | 163 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2009 | 278 | 0.070 |
Why?
|
| Time Factors | 2 | 2015 | 6323 | 0.070 |
Why?
|
| Heart Atria | 1 | 2010 | 316 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 3154 | 0.070 |
Why?
|
| HIV Infections | 1 | 2018 | 1878 | 0.060 |
Why?
|
| Prosthesis Design | 1 | 2009 | 681 | 0.060 |
Why?
|
| Reoperation | 1 | 2009 | 830 | 0.060 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2009 | 546 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 2418 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2002 | 1046 | 0.050 |
Why?
|
| Canada | 1 | 2023 | 287 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2023 | 314 | 0.050 |
Why?
|
| Latin America | 1 | 2021 | 92 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2023 | 369 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 364 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 1357 | 0.040 |
Why?
|
| Private Sector | 1 | 2019 | 24 | 0.040 |
Why?
|
| Financing, Government | 1 | 2019 | 30 | 0.040 |
Why?
|
| Myocardial Reperfusion | 1 | 1999 | 73 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2019 | 101 | 0.040 |
Why?
|
| Serum | 1 | 2018 | 46 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2018 | 152 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 458 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 2043 | 0.030 |
Why?
|
| Troponin T | 1 | 2018 | 282 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 216 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 312 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 428 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2002 | 4406 | 0.030 |
Why?
|
| Critical Care | 1 | 2021 | 655 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 247 | 0.030 |
Why?
|
| Infant | 2 | 2021 | 12384 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2016 | 198 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 752 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 374 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 3715 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 867 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 1286 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 271 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 1530 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 4396 | 0.020 |
Why?
|
| Survival Rate | 2 | 2009 | 2055 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 1047 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 2900 | 0.020 |
Why?
|
| Organ Size | 1 | 2010 | 436 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2010 | 453 | 0.020 |
Why?
|
| Heart Failure | 1 | 2002 | 2297 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1052 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2021 | 8163 | 0.020 |
Why?
|
| Animals | 3 | 2016 | 34235 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2010 | 659 | 0.010 |
Why?
|
| Captopril | 1 | 2002 | 28 | 0.010 |
Why?
|
| Heart Septum | 1 | 2002 | 54 | 0.010 |
Why?
|
| Ligation | 1 | 2002 | 135 | 0.010 |
Why?
|
| Cardiomegaly | 1 | 2002 | 135 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 224 | 0.010 |
Why?
|
| Mice | 2 | 2002 | 17645 | 0.010 |
Why?
|